- Home
- CRDF vs NVCT Comparison
CRDF vs NVCT Comparison
Compare CRDF & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- NVCT
- Stock Information
- Founded
- CRDF 1999
- NVCT 2020
- Country
- CRDF United States
- NVCT United States
- Employees
- CRDF N/A
- NVCT N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- CRDF Health Care
- NVCT Health Care
- Exchange
- CRDF Nasdaq
- NVCT Nasdaq
- Market Cap
- CRDF 144.4M
- NVCT 167.0M
- IPO Year
- CRDF N/A
- NVCT 2022
- Fundamental
- Price
- CRDF $2.00
- NVCT $6.26
- Analyst Decision
- CRDF Strong Buy
- NVCT Strong Buy
- Analyst Count
- CRDF 5
- NVCT 3
- Target Price
- CRDF $11.10
- NVCT $15.33
- AVG Volume (30 Days)
- CRDF 1.1M
- NVCT 66.5K
- Earning Date
- CRDF 11-06-2025
- NVCT 11-04-2025
- Dividend Yield
- CRDF N/A
- NVCT N/A
- EPS Growth
- CRDF N/A
- NVCT N/A
- EPS
- CRDF N/A
- NVCT N/A
- Revenue
- CRDF $545,000.00
- NVCT N/A
- Revenue This Year
- CRDF N/A
- NVCT N/A
- Revenue Next Year
- CRDF N/A
- NVCT N/A
- P/E Ratio
- CRDF N/A
- NVCT N/A
- Revenue Growth
- CRDF N/A
- NVCT N/A
- 52 Week Low
- CRDF $1.90
- NVCT $4.44
- 52 Week High
- CRDF $5.64
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- CRDF 48.21
- NVCT 43.92
- Support Level
- CRDF N/A
- NVCT $6.15
- Resistance Level
- CRDF $2.27
- NVCT $6.61
- Average True Range (ATR)
- CRDF 0.11
- NVCT 0.26
- MACD
- CRDF -0.04
- NVCT 0.01
- Stochastic Oscillator
- CRDF 87.89
- NVCT 15.07
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.